8-K: Premier, Inc. to Go Private in $2.6B Patient Square Deal

Premier, Inc. has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash, valuing the transaction at approximately $2.6 billion.

Summary

• Premier, Inc. will be acquired by Premium Parent, LLC, an affiliate of Patient Square Capital, for $28.25 per share in cash.
• The total transaction is valued at approximately $2.6 billion.
• The offer price represents a 23.8% premium to Premier's 60-day volume-weighted average price as of September 5, 2025.
• Premier's Board of Directors unanimously approved the merger agreement.
• Upon consummation, Premier Class A Common Stock will be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934.
• Outstanding options to purchase shares will be cancelled for no consideration.
• Restricted Stock Unit (RSU) awards granted before August 16, 2025, will be converted into a cash payment equal to the number of shares multiplied by the Merger Consideration.
• RSU awards granted on or after August 16, 2025, will be cancelled for no consideration.
• Performance Share Unit (PSU) awards granted before August 16, 2025, will be converted into a cash payment based on specific performance percentages (68.75% for non-NEOs for FY24-26, 0% for NEOs for FY24-26, and 105.17% for FY25-27) multiplied by the Merger Consideration.
• PSU awards granted on or after August 16, 2025, will be cancelled for no consideration.
• The Company's Employee Stock Purchase Plan (ESPP) will terminate, with accumulated contributions used to purchase shares on a final exercise date no later than three business days prior to the Closing Date.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant premium offered to shareholders, the unanimous board approval, and the strategic rationale presented by management for enhanced financial flexibility and innovation under private ownership. While some equity awards are cancelled, the overall tone and financial terms for public shareholders are favorable.

Positives

• Stockholders will receive an immediate and certain cash value of $28.25 per share.
• The acquisition price represents a significant 23.8% premium to Premier's 60-day volume-weighted average price as of September 5, 2025.
• The Board of Directors unanimously approved the transaction, determining it to be fair and in the best interests of the company and its stockholders.
• Transitioning to private ownership is expected to enhance financial flexibility and provide additional resources to accelerate product portfolio advancement and tech-enablement.
• The transaction is not subject to a financing condition, reducing uncertainty regarding funding.
• Patient Square Capital is a dedicated healthcare investment firm, suggesting strategic alignment and industry expertise for Premier's future growth.

Negatives

• Premier will suspend the declaration and distribution of common stock dividends in future quarters.
• Outstanding stock options and certain equity awards (RSU and PSU awards granted on or after August 16, 2025) will be cancelled for no consideration.
• Named Executive Officers (NEOs) will receive 0% of target shares for PSU awards covering the fiscal year 2024 through 2026 performance period.
• Delisting from NASDAQ will result in the loss of public market liquidity for shareholders.
• The transaction involves significant transaction costs and potential for litigation or regulatory actions.

Risks

• Inability to consummate the merger within the anticipated time period, or at all, due to failure to obtain required regulatory approvals (e.g., HSR Act) or stockholder approval.
• Risk that announcements relating to the merger could have adverse effects on the market price of Premier Class A Common Stock.
• Disruption from the merger making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and other business partners.
• Occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Risks related to disruption of current plans and operations or the diversion of management's attention from ongoing business operations due to the merger.
• Significant transaction costs associated with the merger.
• Risk of litigation and/or regulatory actions related to the merger or unfavorable results from currently pending or future litigation and proceedings.
• The obligation of Parent and Merger Sub to consummate the Merger is conditioned upon there being no continuing Material Adverse Effect on Premier.

Future Outlook

Premier anticipates that transitioning to private ownership will enhance its financial flexibility and provide additional resources. This will accelerate the advancement and tech-enablement of its product portfolio, allow the company to capitalize on emerging opportunities, and continue innovation in the rapidly evolving healthcare landscape. The company aims to build on its progress in delivering results for members, contracted suppliers, customers, and other stakeholders.

Management Comments

• Richard Statuto, Premier's Board Chair: "We are pleased to have reached this agreement and delighted that Patient Square recognizes and is committed to enhancing Premier's integral role in the U.S. health care system. The Board unanimously approved this transaction, after careful consideration of a wide range of strategic alternatives in recent years and consultation with our financial and legal advisors. We believe this transaction is in the best interests of Premier and its stockholders and, upon closing, will deliver immediate and certain value to our stockholders, while simultaneously providing the Company with access to additional capital that can accelerate the support and services provided to members and other customers during this critical time in health care."
• Michael J. Alkire, Premier's President and CEO: "Since going public in 2013, Premier has leveraged our access to capital to build unmatched supply chain expertise, world-class technology, and nationally recognized advisory capabilities that enable our members to continuously improve their cost, quality, and operational efficiencies. Now, as the health care landscape continues to rapidly evolve, transitioning to private ownership will once again enhance the Company's financial flexibility and provide additional resources to accelerate the advancement and tech-enablement of our product portfolio, capitalize on emerging opportunities and continue pushing the envelope of innovation. I am proud of everything our team has achieved and look forward to building on our progress as we continue delivering real results for our members, contracted suppliers, customers and other stakeholders."
• Neel Varshney, M.D., Patient Square Founding Partner: "We have long admired Premier as an innovator of essential services and products to its members, which are leading institutions and providers in the U.S. health care system. Our team sees tremendous opportunity for Premier to continue growing its differentiated portfolio in supply chain services, data and technology offerings, and consulting solutions that deliver value to patients, and we look forward to working closely with the team as a private company."

Industry Context

The announcement highlights the "rapidly evolving health care landscape" as a key driver for the transaction, suggesting a broader industry trend towards consolidation and private investment to gain financial flexibility and resources. This allows companies to accelerate technology adoption and innovation in healthcare supply chain services, data analytics, and consulting solutions. Patient Square Capital's specialization in healthcare investments further underscores this industry-specific strategic move.

Management Changes

Corporate Governance

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the merger.
• Risk of unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.

Related Party Transactions

• No related party transactions since June 30, 2024, that would be required to be disclosed under Item 404 of Regulation S-K have been disclosed in the Company Reports filed as of the date of this Agreement.
• No shareholder and management arrangements (including as to continuing employment) between Parent/Merger Sub and Premier's shareholders, directors, or officers, other than the merger agreement itself or as expressly authorized by the Company Board, are in place as of the agreement date.

Stakeholder Impact

• **Shareholders**: Will receive $28.25 per share in cash, representing a 23.8% premium, providing immediate and certain value. However, they will lose future public market participation and liquidity.
• **Employees**: Continuing employees will receive comparable base salary/wage, annual target cash bonus opportunities, and substantially comparable aggregate employee benefits (excluding certain types) for at least one year post-closing. Service credit for eligibility, vesting, paid time off, and severance will be recognized.
• **Equity Award Holders**: Holders of stock options and certain RSU/PSU awards (granted on or after August 16, 2025) will have their awards cancelled for no consideration. Holders of other RSU/PSU awards will receive cash payments based on the Merger Consideration and specific performance metrics.
• **Customers/Members**: Expected to benefit from additional capital and resources under private ownership, accelerating support, services, product portfolio advancement, and tech-enablement.
• **Suppliers/Vendors**: Potential for disruption in existing business relationships due to the change in ownership and operational focus.

Next Steps

• Premier will prepare and file a preliminary proxy statement (Schedule 14A) with the SEC within 25 business days of the agreement date.
• Premier will respond to SEC comments on the proxy statement and file the definitive proxy statement.
• Premier will mail the definitive proxy statement to its stockholders.
• Premier will convene a stockholders meeting to vote on the adoption of the merger agreement.
• Parent and Premier will make all necessary filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 within 20 business days and seek early termination of the waiting period.
• Parent and Premier will cooperate to obtain all other required regulatory approvals.
• Premier will deliver a payoff letter for its existing credit agreement at least one business day prior to the Closing Date.
• The transaction is expected to close by the first quarter of calendar year 2026.
• Upon completion, Premier Class A Common Stock will be delisted from NASDAQ and deregistered under the Exchange Act.

Key Dates

Recommendation

The unanimous approval by Premier's Board of Directors and the substantial 23.8% premium offered over the recent 60-day volume-weighted average price provide a clear and attractive cash exit for existing shareholders. Holding the stock until the expected closing in the first quarter of calendar year 2026 allows shareholders to realize this premium, assuming the transaction successfully navigates regulatory approvals and other customary closing conditions. For investors seeking immediate liquidity or who believe the deal spread is insufficient for the remaining risks, selling might be considered, but for those comfortable with the deal's certainty, holding is appropriate to capture the announced value.

Keywords

Premier Inc., PINC, Patient Square Capital, Merger, Acquisition, Healthcare, Supply Chain, Technology, Consulting, Private Equity, SEC Filing, 8-K, Delisting, Stockholder Approval, Regulatory Approval, Equity Awards, Cash Acquisition